HC Wainwright Cuts Cytosorbents (NASDAQ:CTSO) Price Target to $0.75

Cytosorbents (NASDAQ:CTSO) had its price objective lowered by HC Wainwright from $1.00 to $0.75 in a report released on Friday,Benzinga reports. The firm currently has a neutral rating on the medical research company’s stock.

CTSO has been the subject of a number of other research reports. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a research report on Tuesday, September 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cytosorbents in a research note on Tuesday, October 14th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $5.38.

Cytosorbents Stock Down 0.8%

NASDAQ:CTSO opened at $0.66 on Friday. The company has a debt-to-equity ratio of 1.24, a current ratio of 2.34 and a quick ratio of 1.96. The firm’s 50-day moving average price is $0.87 and its 200-day moving average price is $0.95. The company has a market capitalization of $41.42 million, a PE ratio of -3.88 and a beta of 1.28. Cytosorbents has a 1-year low of $0.60 and a 1-year high of $1.61.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Friday, January 3rd. The medical research company reported ($0.08) EPS for the quarter. Cytosorbents had a negative return on equity of 111.97% and a negative net margin of 25.58%.The business had revenue of $8.61 million for the quarter. On average, equities analysts predict that Cytosorbents will post -0.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Cytosorbents

Several hedge funds have recently made changes to their positions in CTSO. Avenir Corp increased its holdings in shares of Cytosorbents by 0.3% in the second quarter. Avenir Corp now owns 5,058,537 shares of the medical research company’s stock valued at $6,475,000 after purchasing an additional 13,619 shares during the period. Goldman Sachs Group Inc. increased its holdings in Cytosorbents by 149.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after buying an additional 37,519 shares during the period. CM Management LLC lifted its stake in Cytosorbents by 3.1% during the 3rd quarter. CM Management LLC now owns 1,288,128 shares of the medical research company’s stock valued at $1,203,000 after acquiring an additional 38,128 shares during the period. Vanguard Group Inc. lifted its stake in Cytosorbents by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after acquiring an additional 79,535 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in shares of Cytosorbents in the 3rd quarter valued at $105,000. 32.87% of the stock is owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.